Assets Under Advice | Fees for 3years | |
35 lacs to 99 lacs | 3% + GST | |
1 Cr to 2.99 Cr | 2.5% + GST | |
3 Cr to 9.99 Cr | 2% + GST | |
10 Cr + | Customised Fees | |
GST @ 18% | ||
|
Please contact us for details | ||
|
AstraZeneca Pharma India, a leading biopharmaceutical company, has launched FORXIGA (dapaglifozin), a breakthrough treatment for Type 2 diabetes mellitus. It is available in the markets from May 2015.
FORXIGA belongs to a new class of Type 2 diabetes mellitus medication-a highly selective inhibitor of sodium-glucose cotransporter 2 (SGLT2). It has an unique insulin independent mode of action that helps remove excess glucose from the body via urine which is associated with reductions in glycated haemoglobin (HbA1c), weight and systolic blood pressure. Globally, FORXIGA is the first medicine in the new SGLT2 inhibitor class to gain regulatory approval for the treatment of Type 2 diabetes mellitus.
FORXIGA tablets are indicated as a once-daily oral medication to improve glycaemic control in adult patients with Type 2 diabetes mellitus. FORXIGA is indicated to be used as an adjunct to diet and exercise in combination with other glucose-lowering medicinal products, including insulin, or as a monotherapy in metformin-intolerant patients.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1675.60 |
Dr. Reddys Lab | 1094.50 |
Cipla | 1410.70 |
Lupin | 1920.00 |
Zydus Lifesciences | 841.15 |
View more.. |